Medical Advisory Board
Alpha-1 Canada is committed to providing information and support to people affected by alpha-1 antitrypsin deficiency; informing the medical community about alpha-1 antitrypsin deficiency; and to generating broad awareness about this genetic liver, lung and skin disease.
We are pleased to present the Alpha-1 Canada Medical Advisory Board, a team of leading physicians and researchers willing and able to assist in providing the accurate and timely the information the Alpha-1 Canada Community needs.
Chairperson: Dr. Kenneth R. Chapman
Dr. Chapman is a Professor of Medicine at the University of Toronto and an internationally respected researcher in the field of asthma and airway diseases. Dr. Chapman is also Director of the Canadian Registry for Alpha-1 Antitrypsin Deficiency. More information about Dr. Chapman.
Dr. Jean Bourbeau
Dr. Bourbeau is associate professor in the Department of Medicine and the Department of Epidemiology and Biostatistics and Occupational Health at McGill University. More information about Dr. Bourbeau.
Dr. Simon Ling
Dr. Ling is Associate Professor of Paediatrics at the Hospital for Sick Children, University of Toronto. Additionally, Dr. Ling collaborates in studies of the genetic determinants of liver disease due to cystic fibrosis and alpha-1 antitrypsin deficiency. More information about Dr. Ling.
Dr. Marsha Speevak
Dr. Speevak is Assistant Professor, University of Toronto, Department of Laboratory Medicine and Pathobiology. Dr. Speevak’s laboratory at Credit Valley Hospital provides targeted genotyping (S and Z variants) as well as full gene sequencing of SERPINA1, the gene responsible for alpha-1-antitrypsin deficiency. More information about Dr. Speevak